X0306 4 2021-06-28 0 0001826457 Monte Rosa Therapeutics, Inc. GLUE 0001746342 Chang Carmen 2855 SAND HILL ROAD MENLO PARK CA 94025 0 0 1 0 Common Stock 2021-06-28 4 C 0 2715968 A 2715968 I See Note 2 Common Stock 2021-06-28 4 C 0 3257328 A 5973296 I See Note 2 Common Stock 2021-06-28 4 C 0 669002 A 6642298 I See Note 2 Common Stock 2021-06-28 4 P 0 1050000 19.00 A 7692298 I See Note 2 Series A-2 convertible preferred stock 2021-06-28 4 C 0 9588725 D Common Stock 2715968 0 I See Note 2 Series B convertible preferred stock 2021-06-28 4 C 0 11500000 D Common Stock 3257328 0 I See Note 2 Series C convertible preferred Stock 2021-06-28 4 C 0 2361912 D Common Stock 669002 0 I See Note 2 Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest. /s/ Sasha Keough, attorney-in-fact 2021-06-30